Related Experiment Video
Updated: Jul 3, 2026
03:37
Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
Published on: December 20, 2024
Duodenal malignant somatostatinoma
A M Ferrante1, D Frontera, G B Doglietto
1Istituto di Clinica Chirurgica, Policlinico A. Gemelli, L. go A. Gemelli, 8- Rome 00168, Italy.
Summary
A rare duodenal somatostatinoma, a type of neuroendocrine tumor, was hormonally silent. Despite debated chemotherapy effectiveness, the patient experienced a surprising positive outcome from treatment.
Area of Science:
- Gastroenterology
- Oncology
- Endocrinology
Background:
- Duodenal somatostatinomas are rare neuroendocrine neoplasms.
- These tumors are often hormonally silent, presenting diagnostic challenges.
- Limited data exists on the natural history and optimal therapies for duodenal somatostatinomas.
Purpose of the Study:
- To describe a case of a hormonally silent duodenal somatostatinoma.
- To review the clinical features, natural history, and therapies of these rare neoplasms.
- To discuss the potential role of chemotherapy in managing duodenal somatostatinomas.
Main Methods:
- Case report presentation.
- Comprehensive literature review of duodenal somatostatinomas.
- Analysis of treatment outcomes, including chemotherapy.
Main Results:
- A case of a hormonally silent duodenal somatostatinoma is presented.
- Review highlights variable clinical presentations and rarity.
- The patient demonstrated an unexpected positive response to chemotherapy.
Conclusions:
- Hormonally silent duodenal somatostatinomas require high clinical suspicion.
- Chemotherapy, though debated, may offer a surprising benefit in select cases.
- Further research is needed to establish definitive therapeutic guidelines.